On Friday, Shares of MiMedx Group Inc (NASDAQ:MDXG), lost -2.46% to $9.50.
MiMedx Group, declared that MiMedx administration has responded to numerous questions relative to its second quarter report. From the Company’s standpoint, these questions have already been addressed after first and second quarter conference calls. However, there has been some misinterpretation and misinformation since this quarter’s press release and conference call which the Company seeks to clarify.
Second quarter revenue of $45.7 million grew almost 80%, which was above analyst consensus and only $321,000 below the Company’s high-end guidance. While the Company has often exceeded its guidance over the last three years, there have been a number of quarters where the revenue was in the upper end of the range as it was this quarter.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix.
Shares of Dreamworks Animation Skg Inc (NASDAQ:DWA), declined -2.04% to $20.20, during its last trading session.
DreamWorks Animation SKG, stated revenues for the quarter ended June 30, 2015 of $170.8 million, representing an enhance of 39.7% from the same period in 2014. In addition, DWA stated an adjusted(b) operating loss of ($1.0) million and adjusted(b) net loss attributable to DWA of ($11.6) million or an adjusted(b) loss of ($0.13) per share. Adjusted financial results exclude a $20.9 million pre-tax charge associated with Company’s Restructuring Plan declared on January 22, 2015.
Counting the impact of the Restructuring Plan, DWA stated an operating loss of ($21.8) million and stated net loss attributable to DWA of ($38.6) million, or ($0.45) per share for the quarter ended June 30, 2015. Of the restructuring-related charges totaling $20.9 million or a loss of ($0.25) per share, $2.4 million was due to employee termination and other employee-related costs, $10.9 million was related to accelerated depreciation and amortization charges associated with the closure of our Redwood City facility, and $7.6 million was primarily related to excess staffing and other costs associated with formerly declared changes in the feature film slate.
DreamWorks Animation SKG, Inc. engages in the development, production, and exploitation of animated films and their associated characters worldwide. The company operates in four segments: Feature Films, Television Series and Specials, Consumer Products, and New Media.
At the end of Friday’s trade, Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP), lost -10.98% to $2.35.
OHR Pharmaceutical, stated results for its third fiscal quarter ended June 30, 2015.
“The clinical programs for our lead candidate OHR-102 continue to yield positive visual acuity data and there is now a growing body of evidence demonstrating that OHR-102 has the potential to be an important treatment option for patients with various back of the eye diseases,” said Jason S. Slakter, MD, newly designated Chief Executive Officer of Ohr Pharmaceutical. “During the quarter, we were happy to report additional results from the Phase II IMPACT trial at the ARVO and ASRS meetings, counting new data demonstrating visual acuity benefits in patients with classic CNV containing lesions in addition to lesions with an occult CNV area less than 10mm2. In addition, data from an investigator sponsored study showed that OHR-102 combination therapy improved visual acuity gains in patients with retinal vein occlusion.”
Corporate Highlights for the Quarter Ended June 30, 2015, and Recent Events
- In April, presented detailed results on OHR-102 from the IMPACT study at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Colorado
- Topically administered OHR-102 combination therapy led to improved visual function in patients with wet AMD.
- Patients with classic containing CNV demonstrated a mean gain in visual acuity at month nine of +11 letters for the OHR-102 combination arm and +5 letters with Lucentis(R) monotherapy, a clinically meaningful benefit of 6 letters. In addition, 44% of patients treated with OHR-102 combination therapy gained 3 or more lines of vision contrast to only 29% in the Lucentis monotherapy group at month 9.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
Finally, Cimarex Energy Co (NYSE:XEC), ended its last trade with -1.75% loss, and closed at $110.91.
Cimarex Energy Co., stated a second quarter 2015 net loss of $600.2 million, or $6.47 per diluted share, counting a non-cash impairment of oil and gas properties. The adjusted second quarter net income was $14.4 million, or $0.15 per diluted share. Second quarter 2015 adjusted cash flow from operations was $252.4 million as compared to $443.1 million a year ago.
Total company production averaged 1.0 billion cubic feet equivalent (Bcfe) per day during the second quarter, a 22 percent enhance from second quarter 2014. Year-over-year natural gas volumes raised 14 percent, oil volumes grew 35 percent, and NGL volumes were up 25 percent.
Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Texas, Oklahoma, and New Mexico. The company owns interests in 3,240 net productive oil and gas wells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
